Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Lilly Details Revenue Growth, Cuts

Thursday, December 15, 2016 12:21 PM EDT
By Andy Ober
Lilly Details Revenue Growth, Cuts Lilly completed the CoLucid acquisition in March.

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is reaffirming previously-announced financial expectations through the remainder of the decade, including at least 5 percent average annual revenue growth. Despite shelving a once-promising potential Alzheimer’s disease treatment because of disappointing late-stage clinical trial results, the company says it still has the potential to launch 20 new products in the period between 2014 and 2023. Inside INdiana Business has learned that dropping the development of solanezumab will result in 500-550 job cuts.

IIB has learned most of those cuts will be sales positions added in anticipation of positive results for the treatment.

Lilly says it is expecting 2017 revenue between $21.8 billion and $22.3 billion, with growth driven by recently-launched products. The company says it has launched seven products since 2014, with one under regulatory review. New products include Trulicity (diabetes), Cyramza (oncology), Taltz (psoriasis) and Lartruvo (oncology). Diabetes treatment Basaglar is expected to launch in December 2017.

While Lilly will no longer seek regulatory approval for solanezumab, the company says it remains committed to Alzheimer’s care and has multiple assets in clinical development. Last week, Lilly announced a codevelopment agreement with AstraZeneca PLC (NYSE: AZN) involving an antibody currently in Phase 1 trials.

In July, Lilly Chief Executive Officer John Lechleiter announced plans to retire in January. Longtime Lilly executive Dave Ricks will become CEO on January 1 and chairman of the board on June 1. Lechleiter will be a guest this weekend on Inside INdiana Business Television.

Story Continues Below

Most Popular Stories

  • Gahl: Developments show confidence in downtown Indy

  • Did the Federal Reserve stick the (soft) landing?

  • United Way awards $1 million to central Indiana nonprofits

  • IU names University of Missouri vice chancellor to lead Indy campus

Perspectives

Did the Federal Reserve stick the (soft) landing?

Did the Federal Reserve stick the (soft) landing?

When Federal Reserve Chair Jerome Powell began increasing interest rates in early 2022, few economists predicted a resilient economic response. It wasn't a matter of "if" we would be pushed into a recession but how bad the recession would be. Nearly two years into the steepest increase in interest rates in over 40 years, can we now say we've achieved a soft landing? Or is this a delayed economic response with a 2024 recession certain to come?...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service